Page 2 - Pharma Sector News Today

India boasts numerous top-tier, high-quality companies and presents a wide array of opportunities for long-term investors, highlighting the untapped potential.

Exploring the growth potential of the Indian pharmaceutical sector requires careful consideration of risks and uncertainties, demanding thorough research before investing in a pharma fund.

The Indian pharmaceutical sector holds significant growth potential, yet it is crucial to acknowledge the accompanying risks and uncertainties. Before making any commitments to invest in a pharma fund, thorough research is imperative.

Samir Arora of Helios Capital discusses valuation, investment strategies, and risk management in the Indian market. He emphasizes the missed opportunity in the pharma sector and the underperformance of the consumer sector. He said willing to buy consumer stocks at 40-50 PE if the companies are growing 25-30% per annum for the next few years at least. That is the only thing we will buy in consumer even if the valuations are high. That is why we have Zomato and Varun Beverages .

Andrew Holland, CEO of Avendus Capital Alternate Strategies, believes that PSU banks are performing well while private banks face challenges. He also comments on the rotational market, pharma and IT sectors, OMCs, metal stocks, and the global market dynamics. He also says, he likes metal stocks a lot, That is an area which will see continued rise over the course of the next month.

Sandip Sabharwal discusses the pharma sector, IndiGo stock, PSU banks, hospital stocks, consumer sector, and the performance of ABFRL and Trent. Sabharwal says Aurobindo Pharma has some active accounting and the injectable facility issue may drag on some more time. Hindalco has been on a tear ex of this sell-off which has happened now, despite the fact that the entire aluminium, copper and the metal basket has gone nowhere.

Mukhtar Abbas Naqvi expressed admiration for the collective commitment of the government, society, and medical fraternity in tackling the Covid-19 pandemic. He credited Prime Minister Narendra Modis alertness in ensuring preparedness and quick action. Naqvi praised the governments efforts in providing quality healthcare and its philosophy of leaving no one behind.

Sumeet Bagadia of Choice Broking has chosen Cipla as his ‘Valentines Day 2024 Pick’. Bagadia has recommended a ‘Buy’ on the pharma stock at ₹1,450 and up to ₹1,415 for a target price of ₹1,600 to ₹1,660.

The review highlighted structural reforms and digital infrastructure development as key drivers of economic growth, citing examples such as the Aarogya Setu and CoWIN apps that aided pandemic response

The government aims to offer support to pharmaceutical manufacturers to ensure the global minimum tax presents "the smallest possible burden", the Finance Ministry said on Friday, after a decree on modifications to pharma sector taxes was published, state news wire MTI reports.